Wy14643, an agonist for PPARα, downregulates expression of TARC and RANTES in cultured human keratinocytes. Issue 5 (23rd March 2017)

• Record Type: Journal Article
• Authors: Zhang, Wei; Sakai, Takashi; Fujiwara, Sakuhei; Hatano, Yutaka
• Is Part Of: Experimental dermatology. Volume 26:Issue 5(2017)
• Page Start: 457
• Page End: 459
• Publication Date: 2017-03-23
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13245
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Beneficial effects of Wy14643, an agonist for peroxisome proliferator‐activated receptor (PPAR)α, on permeability barrier homeostasis‐related functions of keratinocytes such as up‐regulation of epidermal differentiation‐related molecules and lipid synthesis, have been demonstrated. The present study demonstrated that Wy14643 reduced the expression of thymus and activation‐related chemokine (TARC) and regulated on activation normal T cell expressed (RANTES) in both single‐ and 3D‐cultured human keratinocytes. The combined data of the present and previous studies support the notion that Wy14643 could be a therapeutic agent that might simultaneously and directly modulate permeability barrier dysfunction and allergic inflammation in the pathogenesis of atopic dermatitis. As for the anti‐microbial barrier function, the present study demonstrated that Wy14643 up‐regulated expression of the anti‐microbial peptide, human β defensin 3, in cultured human keratinocytes only in mRNA levels but not in protein ones, suggesting that Wy14643 might not directly account for the up‐regulation of the anti‐microbial peptide which has been reported in vivo.